Literature DB >> 26522733

The association and prognostic relevance of cancerous inhibitor of protein phosphatase 2A and inflammation in tongue squamous cell carcinoma.

Miia Seppälä1, Sanni Tervo2, Konsta Pohjola2, Jussi Laranne3, Heini Huhtala4, Sanna Toppila-Salmi1,5, Timo Paavonen2,6.   

Abstract

Cancerous inhibitor of protein phosphatase 2A (CIP2A) prevents proteolytic degradation of a universal transcription factor, c-Myc. Strong CIP2A expression associates with poor prognosis in early-stage tongue cancer and in other cancers. The aim of this study was to evaluate CIP2A and mucosal inflammation in tongue hyperplasia, in tongue cancer, and in its metastasis. Retrospective tongue and lymph node specimens (n = 105) were stained immunohistochemically with polyclonal antibody anti-CIP2A. CIP2A staining intensity and inflammation were assessed semi-quantitatively with light microscopy. CIP2A was similarly detected in tongue cancer and tongue hyperplasia, whereas local inflammation was stronger in cancer (p = 0.000). CIP2A expression was increased in metastasized cancer compared to non-metastasized (p = 0.019). Markers for poorer survival were tumor size of ≥20 mm, presence of metastasis and nodal CIP2A (p = 0.031, p = 0.000, p = 0.042). Cancer patients aged ≥60 with increased inflammation predicted poor survival (p = 0.037). CIP2A and inflammation might play a role in progression of tongue cancer.
© 2015 APMIS. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Cancerous inhibitor of protein phosphatase 2A; immunohistochemistry; inflammation; tongue squamous cell carcinoma; tongue squamous cell hyperplasia

Mesh:

Substances:

Year:  2015        PMID: 26522733     DOI: 10.1111/apm.12462

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  1 in total

Review 1.  Oral cancer: changing the aim of the biopsy in the age of precision medicine. A review.

Authors:  Roberto Bruschini; Fausto Maffini; Fausto Chiesa; Daniela Lepanto; Rita De Berardinis; Francesco Chu; Marta Tagliabue; Gioacchino Giugliano; Mohssen Ansarin
Journal:  Acta Otorhinolaryngol Ital       Date:  2021-04       Impact factor: 2.124

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.